Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18232147 | 0.88 | PIK3CD (0.62) | PIK3CDMEN1KMT2ACYP1A2MAPK1 | |
| SCHEMBL25959313 | 0.87 | PIK3CD (0.47) | PIK3CDMEN1KMT2ACYP1A2MAPK1 | |
| SCHEMBL13519630 | 0.84 | PIK3CD (0.48) | PIK3CDMEN1KMT2APOLBKDM4E | |
| SCHEMBL13181450 | 0.84 | PIK3CD (0.54) | PIK3CDMEN1KMT2ACYP1A2MAPK1 | |
| SCHEMBL11911611 | 0.83 | PIK3CD (0.42) | PIK3CDMEN1KMT2APOLBKDM4E | |
| SCHEMBL12039753 | 0.82 | PIK3CD (0.56) | PIK3CDMEN1KMT2ACYP1A2MAPK1 | |
| SCHEMBL16850424 | 0.82 | PIK3CD (0.56) | PIK3CDMEN1KMT2ACYP1A2MAPK1 | |
| SCHEMBL23374624 | 0.80 | PIK3CD (0.54) | PIK3CDMEN1KMT2ACYP1A2MAPK1 | |
| SCHEMBL23634754 | 0.80 | MEN1 (0.41) | PIK3CDMEN1KMT2APOLBCYP1A2 | |
| SCHEMBL2760168 | 0.80 | KMT2A (0.41) | PIK3CDMEN1KMT2APOLBCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322785-A1 | ADENOSINE A2A AND A2B RECEPTOR DUAL ANTAGONISTS FOR IMMUNO-ONCOLOGY | MERCK SHARP & DOHME LLC (US) | 2023-10-12 | — | — | US | disclosed |
| EP-3154959-B1 | 1-((3S,4R)-4-(3-FLUOROPHENYL)-1-(2-METHOXYETHYL)PYRROLIDIN-3-YL)-3-(4-METHYL-3-(2-METHYLPYRIMIDIN-5-YL)-1-PHENYL-1H-PYRAZOL-5-YL)UREA AS A TRKA KINASE INHIBITOR | ARRAY BIOPHARMA INC (US) | 2019-07-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322785-A1 | ADENOSINE A2A AND A2B RECEPTOR DUAL ANTAGONISTS FOR IMMUNO-ONCOLOGY | ADORA2A, ADORA2B, ADORA1 | PIK3CD 1316/4885MEN1 2984/4885KMT2A 1207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.